

FREE 1



Glucose control with the Inreda AP® in type 1 diabetes: real-world evidence and experience

Key findings


- 1 Time in range increased significantly with 25%
- 2 PAID questionnaire score (measure for diabetes distress) improved from 30.0 to 10.0
- 3 Time below range reduced from 2.31% to 1.36%
- 4 Combined treatment goal (TIR > 70% and TBR < 4%) was achieved by 97.2%



Overview

This study was a multicenter, prospective, single-arm intervention trial conducted over one year in a real-world home setting. Adults aged 18–75 years with type 1 diabetes who had been using flash or continuous glucose monitoring (FGM/CGM) for at least three months were included. Regular diabetes care of the participants served as the control.

Results



Conclusions

The real-world data acquired in this 1 year trial demonstrated that the use of the Inreda AP® was associated with good glycaemic control and lower diabetes distress and could be used safely in people with type 1 diabetes

Published in The Lancet Digital Health

van Bon, A. C., et al. (2024). Bihormonal fully closed-loop system for the treatment of type 1 diabetes: A real-world multicentre, prospective, single-arm trial in the Netherlands. The Lancet Digital Health, 6(4), e272–e280. [https://doi.org/10.1016/S2589-7500\(24\)00002-5](https://doi.org/10.1016/S2589-7500(24)00002-5)

CNT Version D02

FREE 1

Glucose control with the Inreda AP® in type 1 diabetes: real-world evidence and experience

